Adenovirus-Mediated Expression of the p14 Fusion-Associated Small Transmembrane Protein Promotes Cancer Cell Fusion and Apoptosis In Vitro but Does Not Provide Therapeutic Efficacy in a Xenograft Mouse Model of Cancer

Carmen M. Wong¹,², Kathy L. Poulin¹, Grace Tong¹, Carin Christou¹, Michael A. Kennedy¹, Theresa Falls⁴, John C. Bell²,⁴,⁵, Robin J. Parks¹,²,³,⁵*

¹ Regenerative Medicine Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada, ² Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, ON, Canada, ³ Centre for Neuromuscular Disease, University of Ottawa, Ottawa, ON, Canada, ⁴ Cancer Therapeutics Program, Ottawa Hospital Research Institute, Ottawa, ON, Canada, ⁵ Department of Medicine, University of Ottawa, Ottawa, ON, Canada

* rparks@ohri.ca

Abstract

Adenoviruses (Ads) are used in numerous preclinical and clinical studies for delivery of anticancer therapeutic genes. Unfortunately, Ad has a poor ability to distribute throughout a tumor mass after intratumoral injection, and infects cells primarily within the immediate area of the injection tract. Thus, Ad-encoded transgene expression is typically limited to only a small percentage of cells within the tumor. One method to increase the proportion of the tumor impacted by Ad is through expression of fusogenic proteins. Infection of a single cell with an Ad vector encoding a fusogenic protein should lead to syncytium formation with adjacent cells, effectively spreading the effect of Ad and Ad-encoded therapeutic transgenes to a greater percentage of the tumor mass. Moreover, syncytium formation can be cytotoxic, suggesting that such proteins may be effective sole therapeutics. We show that an early region 1 (E1)-deleted Ad expressing reptilian reovirus p14 fusion-associated small transmembrane (FAST) protein caused extensive cell fusion in the replication-permissive 293 cell line and at high multiplicity of infection in non-permissive human lung adenocarcinoma A549 cells in vitro. FAST protein expression in the A549 cancer cell line led to a loss of cellular metabolic activity and membrane integrity, which correlated with induction of apoptosis. However, in an A549 xenograft CD-1 nude mouse cancer model, Ad-mediated FAST gene delivery did not induce detectable cell fusion, reduce tumor burden nor enhance mouse survival compared to controls. Taken together, our results show that, although AdFAST can enhance cancer cell killing in vitro, it is not effective as a sole therapeutic in the A549 tumor model in vivo.
Introduction

Currently, approximately 50% of all cancer patients will succumb to the disease, clearly illustrating the need for new therapeutics. This need is perhaps best exemplified by the fact that approximately two-thirds of all human gene therapy clinical trials are directed towards cancer [1]. One of the most commonly used platforms for gene delivery is adenovirus (Ad). Unfortunately, when injected into a tumor, Ad does not travel far from the injection tract, rarely infecting cells more than 5 mm from the injection site [2]. As for many vector systems used in cancer therapy, this is a common issue [3]. One approach to improve distribution of viral vectors used in cancer therapeutics is through co-expression of fusogenic proteins. Infection of a single cell with a virus encoding a fusogenic protein can cause extensive multinucleated syncytial formation, effectively increasing the area and number of cells transduced by the virus [4]. Mixing of cytoplasmic contents of fusing cells means that any gene product encoded within the vector is efficiently transferred to all cells fused into the syncytium. Moreover, fusogenic proteins can act as effective single-agent therapeutics, as the process of fusion ultimately compromises cell function and induces cell death [4,5]. In the context of oncolytic virus (OV), in addition to normal tumor cell lysis resulting in release of virus, an infected cell can “spread” its infectious payload through direct cell-cell fusion. In studies using such diverse OV as vesicular stomatitis virus (VSV), herpes simplex virus, and vaccinia virus [6,7,8], and fusogenic proteins from human immunodeficiency virus, Newcastle disease virus and gibbon-ape leukemia virus (GALV) [6,9,10], improved efficacy has been achieved.

Several groups have attempted to enhance Ad spread in tumors through expression of cell fusion proteins. Expression of the GALV fusogenic envelope glycoprotein from a replication competent Ad5 based vector promoted cell-cell fusion, enhanced cancer cell killing in vitro and reduced tumor burden in mice harbouring tumor xenografts, relative to the control virus [9]. Expression of the respiratory syncytial virus (RSV) fusion protein from a replication defective Ad vector reduced tumor burden in a mouse model of colorectal cancer [5], suggesting that fusogenic proteins have the added benefit of being effective sole anti-cancer molecules. However, a limitation of this approach is that these fusogenic proteins are relatively large (~2 kb) and may not be easily accommodated in E1-deleted Ad vectors when paired with large upstream regulatory regions necessary to promote tumor-specific expression or multimodal treatments utilizing additional therapeutic genes delivered in the same vector. Ad have a limited cloning capacity; E1-deleted vectors can accommodate at most ~8 kb of foreign DNA [11,12]. As such, smaller proteins that have the ability to cause cell fusion may be more ideal.

A candidate fusogenic protein to enhance the efficacy of Ad for cancer is the p14 fusion-associated small transmembrane (FAST) protein. The p14 FAST protein is a 125 amino acid (375 bp), nonstructural protein from reptilian reovirus that can mediate cell-cell membrane fusion [13]. This fusogenic protein is a type III single pass transmembrane protein with a hydrophobic myristylated N terminus, and a C-terminal domain composed of a highly basic, membrane-proximal region and a C-terminal proline-rich region. Expression of p14 FAST protein in cells results in extensive cell fusion, and induces apoptosis-dependent membrane permeability [13,14]. The FAST protein has already demonstrated an ability to enhance the efficacy of other vector systems for cancer. A VSV encoding p14 FAST protein showed increased replication and neuropathogenesis in vivo compared to the control virus, indicating the FAST protein can act as a virulence factor to promote virus spread [15]. Enhanced efficacy was observed on coinfection of an oncolytic VSVΔ51 [16] expressing p14 FAST protein and a doubly-deleted vaccinia virus (VV) (deficient in the viral thymidine kinase and vaccinia growth factor [17]) [8]. In 786-O kidney cancer cells, coinfection of these two viruses increased the yield of VV titre by ~100 fold relative to the combination of VV and native VSVΔ51, and also
enhanced cell killing in primary human colon tumor cells [8]. The small size of the FAST protein and its demonstrated ability to enhance virus spread and efficacy make it an ideal candidate for helping improve the spread of Ad-encoded gene products through a tumor. In this study, we explore the ability of Ad-mediated expression of p14 FAST protein to promote cell fusion in tissue culture and as a sole therapeutic in a murine xenograft model of cancer.

Materials and Methods

Cell culture

The 293 [18], 293N3S [19] and A549 human lung adenocarcinoma cells were grown in Minimum Essential Medium (MEM) (Sigma Aldrich) containing 10% (v/v) Fetal Bovine Serum (FBS) (Sigma Aldrich), 2mM GlutaMAX (Invitrogen) and 1x antibiotic-antimycotic (Invitrogen). Ad infected cells were maintained in MEM supplemented with 5% FBS, 2mM GlutaMAX and 1x antibiotic-antimycotic.

Adenoviral constructs and adenovirus purification

Serotype 5 Ad constructs used for these experiments are depicted in Fig 1A. All Ad are early-region 1 (E1) and E3 deleted, and were generated using a combination of conventional and RecA-mediated bacterial cloning [20]. To summarize, the vector lacking a transgene and deleted of E1 and E3 regions is denoted as AdEmpty. The AdRFP construct encodes a monomeric Red Fluorescent Protein (mRFP), a kind gift of R. Tsien (University of California San Diego [21]), under control of the cytomegalovirus (CMV) enhancer/promoter and bovine growth hormone polyadenylation sequence (BGHpA) replacing the E1 deletion [22,23]. The FAST cDNA was removed from plasmid pVSV-FAST [8] by digestion with NcoI/NheI, and cloned into Ncol/SpeI digested pPOLY [24], generating pRP2868. pRP2868 was digested with Eagl, and the fragment was cloned into NotI digested pRP2645, an Ad left end shuttle plasmid containing the CMV enhancer/promoter, a multiple cloning site and BGHpA, generating pRP2870. pRP2870 was recombined into an Ad genomic plasmid, pRP2014 [25], generating pRP2872 and the resulting virus AdFAST. A XhoI/SalI fragment from pRP2483 [22] containing a CMV-mRFP-BGHpA expression cassette was cloned into SalI digested pRP2870, with transcription directed opposite to the FAST expression cassette, generating pRP2873. pRP2873 was recombined into the pRP2014 Ad genomic plasmid, generating pRP2874 and the resulting virus AdFAST/RFP. AdFAST-HA is similar to AdFAST, but contains a C-terminal HA epitope tag. The HA tag was added with a glycine linker and amplified from pRP2868 using the sense primer 5’-CCGCCATGGGGAGTGGACC-3’ and antisense primer 5’-CTAACTAGTCTAAGCGTAGTCTGGGACGTCGTATGGGTACGAGCCACCGCCACCAATGGCTGAGACATTATCGATGTTGACG-3’. The resulting PCR fragment was digested with Ncol/SpeI and cloned into pRP2868, replacing the native FAST cDNA, generating pCW100. pCW100 was sequenced to verify its integrity. An Eagl fragment from pCW100 was cloned into NotI digested pRP2645, generating pCW101, and subsequently recombined into the pRP2014 Ad genomic plasmid, generating pCW103 and the resulting virus AdFAST-HA. Vectors were propagated and purified using standard techniques [26].

Analysis of FAST protein expression

293 and A549 cells were seeded at 1x10^6 and 0.8x10^6 cells per 35mm dish, respectively. Next day, the cells were infected for 1 h at a multiplicity of infection (MOI) of 10 with AdEmpty or AdFAST-HA. Following a 48 h incubation, whole cell lysates were collected using the cell lysis buffer as described by Lieber et al. [27]. Samples were separated by 15% SDS-PAGE and
transferred onto a polyvinylidene fluoride (PVDF) membrane (Millipore). The resulting membrane was probed with a mouse anti-HA tag monoclonal antibody (1:1000, Cell Signaling #2367) and goat anti-mouse antibody conjugated to horseradish peroxidase (HRP) (1:10 000, Bio-Rad #170–6516). To confirm Ad replication, the membrane was reprobed for Ad5 fibre (1:20 000 mouse anti-fibre monoclonal antibody, clone 4D2, Neomarkers). The membrane was also probed with antibody to α-tubulin to confirm equal loading (1:5000 rabbit anti-α-tubulin antibody, AbCam #ab15246, 1:5000 goat anti-rabbit IgG conjugated to HRP, Bio-Rad #170–6515). Blots were developed using the Pierce Enhanced Chemiluminescent (ECL) Western Blotting Substrate (Thermo Scientific). Densitometry was performed using AlphaEaseFC (Alpha Innotech).

**AdFAST for Cancer Therapy**

293 cells were plated at a density of 1x10^6 cells per 35mm dish. Cells were infected at an MOI of 1 with AdEmpty or AdFAST the next day for 1 h. Cells were washed two times with PBS before adding 5% FBS/MEM. Whole cell lysates were collected at varying time points using cell lysis buffer as described above and probed for Ad5 fibre to compare adenoviral gene expression between the two vectors. Supernatants were also collected to determine viral progeny titre using plaque assays [26].
Giemsa staining
293 and A549 cells were seeded in 35mm dishes at densities of 1x10^6 and 0.8x10^6 cells per dish, respectively, and grown to confluency. 293 cells were infected at an MOI of 1 with AdEmpty or AdFAST and stained with Giemsa stain (Merck Millipore) 18 hpi. A549 cells were infected at an MOI of 50 with AdEmpty or AdFAST and subjected to Giemsa staining 48 hpi. Stained cells were visualized using the 20x objective of the Zeiss Axiovert 200M microscope. The fusion index was calculated using the formula: (N-S)/T x 100%, where N is the number of nuclei in syncytium, S is the number of syncytia and T is the total number of nuclei [28].

Fluorescence microscopy and quantification
Thirty-five mm dishes of 293 and A549 cells were seeded at a density of 0.6x10^6 cells. Next day, the cells were infected with AdRFP or AdFAST/RFP at varying MOI. The cells were visualized at varying times post infection using a Zeiss Axiovert 200M microscope. Images were taken using a 20x objective and compiled in Adobe Photoshop CS4. For the A549 co-culture assay, A549 cells were infected with AdRFP or AdFAST/RFP at an MOI of 50. After 6 hours, the infected A549 cells were mixed at a 1:1 ratio with A549::WPI cells, which constitutively express the green fluorescent protein (GFP) from an integrated lentivirus vector. Cocultures were observed using fluorescence microscopy at 24 h intervals. Images were captured and processed as described above. Image J [29] was used to calculate the area fluorescing green for coculture experiments.

MTS metabolic activity assays
293 and A549 cells were seeded at 2.5x10^4 and 2x10^4 cells per well, respectively, in 96 well plates. Next day, the cells were infected at varying MOI with AdEmpty or AdFAST in 25 μL inoculum for 1 h, followed by addition of MEM supplemented with 5% FBS to a final volume of 100 μL. Metabolic activity was assessed using the CellTiter 96 AQueous Non-Radioactive Cell Proliferation Assay (Promega) at 72 hpi using a 1 h incubation with MTS substrate (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium). A second set of cells were infected at an MOI of 10 with AdEmpty or AdFAST and the relative metabolic activity was monitored using the MTS assay over 96 h at 24 h intervals. Absorbance was determined at 490 nm using the SpectraMax 190 plate spectrophotometer (Molecular Devices).

Assay of membrane integrity
A549 cells were seeded at a density of 2x10^4 cells per well in 96 well plates and grown to confluency. Medium was removed and cells were infected with AdEmpty or AdFAST at a MOI of 1, 5, 10, 50 or 100 in 25 μL inoculum for 1 h. The VSVΔ51 virus [16] was used as a positive control. Medium was added to a final volume of 125 μL and the cells were incubated at 37°C in 5% CO2 for 72 h. Prior to collecting the supernatants, a series of wells containing uninfected cells were lysed with 9% Triton X-100 to provide a maximum release control. All treatments were completed in triplicate. Fifty μL of supernatant was transferred to a new 96 well plate and the CytoTOX-ONE™ Homogeneous Membrane Integrity Assay kit (Promega) was used to assess membrane integrity. Fluorescence was determined using the 544 nm excitation filter and 590 nm emission filter with a FluoSTAR Galaxy fluorimeter (BMG Labtech).

Analysis of cleaved caspase-3 protein expression
A549 cells were seeded at 0.8x10^6 cells per 35mm dish and grown to confluence. Cells were infected for 1 h with AdEmpty or AdFAST at an MOI of 10. As positive control, cells were
treated with 100 μM etoposide for 24 hr or 1 μM staurosporine for 6 hr. Whole cell lysates were collected at varying time post-infection with 2x Laemmli loading buffer (62.5 mM Tris HCl pH 6.8, 25% glycerol, 2% SDS, 0.01% bromophenol blue, 5% β-mercaptoethanol). Samples were resolved by 15% SDS-PAGE and transferred onto a PVDF membrane (Millipore). Membranes were probed with rabbit anti-cleaved caspase-3 monoclonal antibody (1:1000, Cell Signaling #9664) or full-length caspase 3 (1:1000, Cell Signaling #9662) and 1:5000 goat anti-rabbit IgG conjugated to HRP (Bio-Rad #170–6515). Alpha-tubulin was used as a loading control (1:5000, CalBiochem #CP06, 1:10 000 goat anti-mouse IgG conjugated to HRP, Bio-Rad #170–6516). Blots were developed and densitometry was conducted as described above.

Nude mouse studies

Six week old CD-1 nude mice were obtained from Charles River Laboratories (Wilmington, MA), and allowed to acclimate on site for at least one week prior to initiation of animal procedures. Mice were anesthetized (isoflurane) prior to injection of tumor cells and virus. Mice were injected in the right hind flank with 10⁶ A549 cells resuspended in 100 μL PBS. When tumors reached approximately 5x5mm in size, mice were injected intratumorally with PBS, or 5x10⁸ plaque forming units (pfu) of AdEmpty or AdFAST in 50 μL. Tumor size was monitored three times a week using digital calipers. Endpoint was considered when the tumor reached 1687 mm³ by volume (length x width² / 2) or ulceration was observed. This endpoint was applied to all experiments reported in the manuscript, including the survival analysis. A second group of mice were injected when A549 tumors reached 7x7 to 10x10 mm in size with the same virus dose as above. The second set of mice was sacrificed 5 days post injection for histological analysis of tumor and liver samples. Samples were fixed with 10% formalin overnight and submerged in 70% ethanol until processed. Tissues were processed at the Morphology Unit of the Department of Pathology and Laboratory Medicine at University of Ottawa.

Experimental animals were cared for in the Animal Care Facility at the University of Ottawa. Mice were kept in a conventional animal house in groups of 2–4, with a constant room temperature of 24°C and a 12 h dark/light cycles, and with free access to food and water. Mice were monitored daily by animal facility professionals, and additionally monitored by the researchers once every 3 days for tumor measurement, and daily when tumor size was nearing endpoint (1687 mm³ by volume (length x width² / 2)). Animal facility reported to researchers any identified animal recommended for sacrifice due to advancement of tumor burden or generalized distress. Mice were euthanized or sacrificed using carbon dioxide, followed by cervical dislocation.

Ethics Statement

The animal protocol (ME-2258) was approved by the University of Ottawa Animal Care Committee and conducted according to the guidelines of the Canadian Council on Animal Care’s Guide to the Care and Use of Experimental Animals, and the Animals for Research Act.

Statistical analysis

SigmaStat 2.0 was used to determine statistical significance. One-way ANOVA tests and Tukey’s test were applied when normality was observed while Kruskal-Wallis one-way ANOVA on Ranks was used when samples did not follow a normal distribution. Dunn’s test was used in place of Tukey’s test when required. The student’s t-test was used where applicable. Statistical analyses for the animal studies were conducted using Graphpad Prism 6.0. The log-rank test was used to determine statistical significance of the Kaplan-Meier survival curve. All tests were conducted at p = 0.05.
Results

Ad-mediated FAST expression in mammalian cells causes extensive cell fusion under replicative conditions

The viral constructs used in this study are shown in Fig 1A. All viruses used in this study are deleted of early region 1 (E1) and E3. Such viruses can replicate in the E1-complementing 293 cell line but not in most other cells, including A549 cells. To confirm FAST protein was expressed from our viral constructs, we infected 293 and A549 cells with AdEmpty and AdFAST-HA at an MOI of 10 and examined the relative FAST protein expression 48 hours later by immunoblot of whole cell protein lysates (Fig 1B). As expected, AdFAST-HA produced a protein of appropriate size in both 293 and A549 cells, although the level of FAST protein expression was higher in 293 cells. This is likely due to the increase in template copy number caused by active virus replication in 293 cells.

To confirm that FAST protein expression does not affect Ad replication, we performed a time course of infection and monitored the expression of fibre, a late gene that is expressed only after active DNA replication, by immunoblot (Fig 1C) and virus yield by plaque assay (Fig 1D). No difference in fibre expression was observed between AdEmpty and AdFAST infected cells at late time points. In addition, there was no difference in the number of Ad progeny up to 24 hpi as determined using a plaque forming assay (Fig 1D). Thus, FAST protein expression did not affect virus replication and progeny production for an E1-deleted Ad vector in 293 cells.

We next examined whether expression of FAST protein from an Ad vector can promote cell fusion, initially using 293 cells. Both AdEmpty and AdFAST can replicate in this cell line, which provides very high levels of FAST protein expression (Fig 1B). We infected 293 cells with AdEmpty or AdFAST at an MOI of 1 and stained the cells with Giemsa stain 18 hpi (Fig 2A). At this time point, cells infected with AdEmpty showed no discernable difference relative to PBS-treated control cells. In contrast, cells treated with AdFAST showed evidence of cell fusion, and the formation of multinucleated syncytia (fusion index of 99.2%) at this early time point (Fig 2B). With a longer incubation period, the fused cells from the AdFAST/RFP treatment lifted from the plate and adopted a large spherical structure, which was not observed for cells treated with control virus (Fig 2C). Mock infected cells did not show any signs of fusion or fluorescence (not shown). Live imaging analysis of AdRFP- and AdFAST/RFP-infected cells also confirmed AdFAST/RFP-mediated fusion and enhanced cytopathic effect (S1 Movie and S2 Movie). Thus, expression of the FAST protein from an Ad vector in 293 cells caused extensive cell fusion.

We next examined the effect of Ad-mediated FAST protein expression on cell metabolic function. 293 cells were infected at an MOI of 10 with AdEmpty or AdFAST (or treated with PBS), and metabolic activity was examined at 24 h intervals using an MTS assay. As shown in Fig 2D, although treatment with both vectors caused a decrease in metabolic activity relative to PBS-treated cells, AdFAST-treated cells showed a dramatic decrease in metabolic activity compared to AdEmpty at both 24 and 48 hpi. At later time points (72–96 hpi), both viruses showed similar decrements in metabolic activity, likely due to the effects of progressive virus replication in the 293 cell line. Taken together, these data indicate that high-level expression of FAST protein from an Ad vector during replication permissive conditions in the 293 cell line leads to extensive cell fusion and decreased cellular metabolic activity.

Ad-mediated FAST protein expression in A549 cells induces cell-cell fusion

Infection of 293 cells with AdFAST led to high levels of protein expression (Fig 1B), resulting in extensive cell-cell fusion (Fig 2A–2C) and decreased cellular metabolic activity (Fig 2D)
relative to cells treated with AdEmpty. Under non-replicating conditions in A549 cells, Ad-mediated FAST protein expression was noticeably reduced (Fig 1B). We therefore examined whether AdFAST could also mediate cell fusion in this cell line. We used three assays to assess cell fusion. First, A549 cells were infected with AdRFP or AdFAST/RFP at varying MOI and simply visualized at 48 hpi using fluorescence microscopy. Only isolated regions of the AdFAST/RFP-treated monolayer showed large cells indicative of cell fusion (Fig 3A, white arrows). To confirm that cell-cell fusion was occurring in A549 cells, we next performed a cell coculture assay. AdFAST/RFP- or AdRFP-infected A549 cells were cocultured at a 1:1 ratio with A549 cells that constitutively expressed GFP (A549::WPI) (Fig 3B). Incubation of AdRFP-infected cells with A549::WPI cells showed some evidence of merged fluorescence signal (yellow), but this appeared to be exclusively due to cell overlap. In contrast, coculture with AdFAST/RFP-infected cells resulted in large areas of yellow signal, suggesting true fusion into multinucleated syncytium.

Fig 2. FAST protein expression induces extensive cell fusion in 293 cells. A) 293 cells were infected with AdEmpty or AdFAST at an MOI of 1 and stained with Giemsa stain 18 h later. Images were captured using bright field microscopy (20x objective). A region of fused cells for the AdFAST-treated cells is outlined with a dotted line, and several nuclei within the syncytium are indicated with asterisks (*). B) Fusion index of 293 cells infected with AdEmpty or AdFAST. The fusion index for two fields of view were determined, and the average with the standard deviation is depicted in the graph. C) 293 cells were infected with AdRFP or AdFAST/RFP at MOI 10 and observed using fluorescence microscopy at 48 h post infection. All images were taken using a 20x objective. D) 293 cells were infected at a MOI of 10 with AdEmpty or AdFAST and relative metabolic activity was determined using an MTS assay over a 96 h interval every 24 h. Experiments were completed in triplicate and the average of three independent experiments is shown (n = 3). Values were normalized to mock infected cells at 24 hpi. Error bars denote the standard error of the mean. *p<0.05 compared to mock infected cells. **p<0.05 when comparing AdFAST to AdEmpty infected cells.

doi:10.1371/journal.pone.0151516.g002
Fig 3. Ad-mediated FAST protein expression induces cell fusion in A549 cells. A) A549 cells were infected with AdRFP or AdFAST/RFP at an MOI of 10, 50 or 100. Fluorescence microscopy was used to visualize cells 48 hpi (20x objective). Fused cells are indicated by the white arrows. B) A549 cells infected with AdRFP or AdFAST/RFP at an MOI of 10 were cocultured 6 hpi at a 1:1 ratio with A549 cells constitutively expressing GFP. After 72 h of...
Finally, A549 cells were treated at an MOI of 50 with AdEmpty or AdFAST and, 48 h later, the cells were stained with Giemsa (Fig 3C). Once again, cells infected with AdEmpty showed no discernable difference relative to PBS-treated control. Quantitatively, the fusion index was similar between the PBS and AdEmpty-treated cells (i.e. 2.7% vs 3.7%, respectively) (Fig 3D). In contrast, cells treated with AdFAST showed evidence of cell fusion, and formation of multinucleated syncytia with a fusion index of 97.5%. Although a similar fusion index was observed for 293 and A549 cells, the latter required a high MOI (1 versus 50, respectively), and a longer period of incubation with virus (18 versus 72 hpi, respectively), likely due to the differences in FAST protein expression levels for replicating versus non-replicating virus, respectively. Taken together, these data indicate that Ad-mediated expression of FAST protein in A549 cells does result in cell-cell fusion.

Treatment of A549 cells with AdFAST decreases cellular metabolic activity and membrane integrity, and induces apoptosis

In 293 cells under conditions in which FAST protein is expressed at very high levels, we observed a significant decrease in cellular metabolic activity for AdFAST- relative to AdEmpty-treated cells (Fig 2D). We next asked whether a similar effect was observed in A549 cells in which FAST protein is expressed at lower levels due to the inability of the virus to replicate in this cell line (Fig 1B). A549 cells were infected with AdEmpty or AdFAST at an MOI of 10 and metabolic activity was assessed by MTS assay every 24 h. For PBS-treated cells, we observed a decrease in metabolic activity over the 4-day course of the assay, likely reflecting reduced metabolic activity as the cells reached confluency and underwent contact inhibition (Fig 4A). For cells treated with AdEmpty, no difference in metabolic activity, relative to PBS-treated control cells, was observed. In contrast, AdFAST-treated cells had significantly decreased metabolic activity compared to PBS-treated cells at all time points beyond 24 hr, and reduced activity compared to AdEmpty-infected cells at 48 hpi and 72 hpi (p<0.05) (Fig 4A). These data suggest that under conditions in which FAST protein is expressed at lower levels, time may be required for the protein to accumulate to sufficient levels to mediate fusion and impact metabolic function within the cell. Consistent with this, we observed that treating cells with a higher MOI of AdFAST, which would lead to higher cellular levels of FAST protein, had a greater negative effect on metabolic activity (p<0.05) relative to AdEmpty (Fig 4B). We also examined the metabolic effects of Ad-mediated FAST protein expression in four other human cell lines—kidney adenocarcinoma 786-O, glioblastoma SNB75, and two normal lung cell lines (U87N and U116N [30]) (S1 Fig). For the two human cancer cell line, Ad-mediated expression of FAST caused a modest decrease in metabolic activity in SNB75, but not 786-O (S1 Fig). In contrast, at the highest MOI of 100, treatment of the normal lung cell lines with AdFAST caused a significant decrease in metabolic activity relative to AdEmpty. These results suggest that (1) FAST protein may only be “active” in certain tumor cell types and (2) FAST protein expression should be confined only to cancer cells, as high-level expression of FAST protein in normal cells can be deleterious.

FAST protein-mediated syncytium formation is reported to cause caspase-dependent cell death with a concomitant loss in membrane integrity [14]. To determine whether apoptosis...
was also observed in AdFAST-treated A549 cells, we assayed for cleaved caspase 3, a marker of apoptosis, in crude extracts from treated cells. As expected, treatment of A549 cells for 24 h with 100 μM etoposide or for 6 h with 1 μM staurosporine, known inducers of caspase-mediated cell death, caused cleavage of caspase 3 (Fig 4C). However, the amount of cleaved caspase 3 was modest, and did not increase with higher doses of drug or increased incubation time (data not shown), suggesting our A549 cells are relatively resistant to these apoptotic stimuli.
Treatment of cells with AdEmpty at an MOI of 10 caused evidence of caspase cleavage at both 48 and 72 hpi. However, treatment of A549 cells with AdFAST at the same MOI caused a significant increase in the amount of cleaved caspase 3 at the 72 h time point (Fig 4C). To determine if treatment of A549 cells with AdFAST also resulted in enhanced membrane permeability, we examined LDH release into the supernatant (Fig 4D). Treatment of cells with AdEmpty at an MOI up to 100 did not result in any significant release of LDH while treatment of A549 cells with AdFAST at as low an MOI as 5 led to extensive cell membrane permeability and release of LDH, which was further enhanced with increasing MOI. Thus, the reduced metabolic activity observed for AdFAST-treated cells is accompanied by onset of apoptosis and a concomitant loss in membrane integrity.

FAST protein expression from a replication defective Ad does not improve survival in an A549 xenograft cancer model

Since we had observed significant fusion and cell death in A549 cells infected with AdFAST in vitro, we examined whether FAST protein expression would be beneficial in an in vivo setting. CD-1 nude mice were injected with A549 cells in the right hind flank to establish subcutaneous tumors and were subsequently treated with intratumoral injections of PBS or virus. To determine whether AdFAST induced cell fusion in the A549 subcutaneous tumors, we isolated tumors from mice intratumorally injected with PBS, AdEmpty or AdFAST 5 days post injection. H/E stains showed no obvious difference in virus-injected tumors (Fig 5A). As Ad normally localizes to the liver, liver samples were also subjected to H/E staining, and no differences in pathology was observed between the various treatments (not shown). At day 20 post injection, while AdFAST injected tumors appeared to be slightly smaller in size compared to AdEmpty and PBS injected tumors, this did not reach statistical significance (Fig 5B). Furthermore, AdFAST did not improve survival of treated mice (Fig 5C). Thus, our in vivo studies suggest that expression of FAST protein from an E1-deleted, replication defective Ad vector is not sufficient to achieve a beneficial therapeutic effect in the A549 xenograft tumor model in immunocompromised mice.

Discussion

Ad has shown great promise as a delivery vehicle in many animal models of human disease. Unfortunately, when injected into a solid tumor, Ad remains close to the injection tract, rarely infecting cells more than about 5 mm from the injection site, regardless of dose [2]. To overcome this problem, we investigated whether the cell-cell fusion abilities of the p14 FAST protein could enhance the cell area impacted by Ad. Cell fusion would theoretically allow spread of Ad encoded therapeutic gene products, or Ad itself, to neighbouring cells, potentially enhancing its therapeutic benefits. In addition, since fusogenic proteins can act as effective sole anti-cancer therapeutics [4,5], we also examined the effect of Ad-mediated FAST protein expression on A549 adenocarcinoma cell line viability and in a xenograft nude mouse tumor model.

After confirming FAST protein expression from our Ad constructs (Fig 1B), we examined the effects of FAST protein in 293 cells under conditions where the E1-deleted vector would replicate and yield very high levels of p14 protein. FAST protein expression caused extensive cell fusion (Fig 2) and reduced metabolic activity within the cells (Fig 2D). The exact mechanism by which FAST protein mediates cell fusion has yet to be elucidated. FAST protein traffics through the endoplasmic reticulum/Golgi complex, an event that appears necessary for homomultimerization of the protein [31]. After reaching the plasma membrane, FAST protein localizes to adherens junctions and utilizes cellular cadherins and actin remodeling to promote...
membrane apposition, as the very short extracellular domain of FAST does not appear to play a role in mediating pre-fusion attachment [32]. Through an uncharacterized mechanism, FAST protein promotes hemifusion, initial pore formation and expansion of these structures into stable micropores, and finally syncitium formation. A subfragment of the FAST protein, the 68-residue endodomain generated naturally from proteolytic processing of the full-length protein, can function to enhance pore expansion [33], a process that is sensitive to the membrane curvature-inducing lipid lysophosphatidylcholine [34], and that requires cellular annexin A1 [35]. FAST protein-mediated fusion is reported to be a relatively non-leaky process (i.e. the cell membrane remains largely intact until late in the process); however, extensive syncytium formation induces cell death, which itself may be responsible for the altered membrane integrity [14]. For the GALV fusion protein, syncytia remain viable for up to 2 days after fusion, but then suffer from a collapse of mitochondrial membrane potential and a concomitant severe depletion of ATP which leads to cell death [36]. It was speculated that the GALV may be in part mislocalized to the mitochondria, affecting mitochondrial membrane integrity and ultimately leading to the observed depolarization. Whether FAST protein also impacts upon organelle function, prior to the onset of cell death, has not yet been investigated.

The extensive cell fusion caused by high-level expression of the FAST protein from a replicating Ad vector suggests that the FAST protein may be appropriate for inclusion in oncolytic Ad vectors. In that context, FAST protein expression may help promote spread of the virus throughout the tumor mass, thus circumventing one of the drawbacks of Ad and many other vector systems. For example, complete tumor regression can be achieved with the oncolytic...
adenovirus ONYX-015 with initial infection of as little as 5% of the tumor cells, but these cells must be equally distributed throughout the tumor [37]. Consequently, distribution and efficacy can be improved through use of multiple, sequential injections of vector [37]. FAST protein expression from an oncolytic Ad would not only allow the virus to spread through normal routes (i.e. tumor cell lysis and virus release), but an infected cell can "spread" its infectious payload through direct cell-cell fusion. The small size of the FAST cDNA of only 375 bp, means that large cancer-relevant regulator regions, such as the telomerase reverse transcriptase (TERT) promoter [38], could be easily accommodated in the vector for tumor-specific regulation of the essential E1 region. Alternatively, immunostimulatory genes could be accommodated in an AdFAST oncolytic vector to enhance the therapeutic effect. Such a virus would function through multiple modalities to achieve tumor cell killing and would potentially be more effective than current oncolytic Ad.

In A549 cells, which are non-permissive for replication of these E1-deleted vectors, FAST protein expression caused cell-cell fusion only at relatively high MOI (Fig 3), suggesting that there may be a threshold of FAST expression required for fusion. FAST-mediated fusion requires oligomerization of the protein through its ectodomain, which could explain why high level FAST protein expression is required for its function [31]. The idea of a threshold may be beneficial in the context of an oncolytic Ad where selective replication will increase FAST protein expression to levels high enough to induce fusion only in cancer cells, whereas low level, spurious expression in normal cells would be expected to have little effect. Consistent with this, we observed that a high MOI of AdFAST was required to affect metabolic activity in normal human cells, while low MOI had no effect (S1 Fig). Thus, regulated expression of FAST protein from an oncolytic vector may provide an effective means to enhance Ad distribution through the tumor mass, in addition to contributing to tumor cell killing directly.

In our nude mouse studies, we did not see any obvious signs of fusion in AdFAST injected tumors (Fig 5A). Furthermore, treatment with AdFAST did not lead to a significant decrease in tumor burden or enhance survival compared to control mice (Fig 5B and 5C). Our in vitro studies suggested that high level FAST protein expression is required to achieve significant fusion in A549 cells (Fig 3). It is possible that the difference between the tumor
microenvironment and in vitro conditions affects gene expression from the Ad vector, resulting in lower relative expression of FAST protein in vivo compared to in vitro. Alternatively, the effective multiplicity of infection for cells contained in a tumor, and hence the level of FAST protein expression, may not reach the threshold level required for efficient fusion. Under conditions of active viral replication, FAST protein expression is higher (Fig 1B) and associated with enhanced fusion (Fig 2) and decreased metabolic activity (Fig 2D). This observation once again suggests that FAST protein expression may provide a better effect in the context of a conditional-replicating, oncolytic Ad vector. It is also important to note that, in this study, we are utilizing a tumor model based on immunodeficient mice. Previous studies have shown that fused human cancer cells and the exosome-like syncytiosomes that they release can promote dendritic cell cross presentation and antigen specific T-cell activation [4,40]. Thus, AdFAST may provide a greater therapeutic benefit in an immunocompetent cancer model, where FAST protein-mediated cell fusion and subsequent syncytiosome release may aid in stimulating anti-tumor immunity.

In this study, we showed that Ad vectors can be used to express the p14 FAST fusogenic protein in cancer cells, resulting in direct cell-cell fusion, compromised cell membrane integrity, and enhanced cell death. Our data shows that the ability of the FAST protein to fuse cells, compromise membrane integrity and promote apoptosis is directly related to the FAST protein expression level and cell type. Although a replication-defective vector expressing the FAST protein did not provide a significant therapeutic benefit in a xenograft model of cancer, our study suggests that the FAST protein may enhance the efficacy and spread of oncolytic Ad, where vector replication will increase FAST protein expression, or synergize with chemotherapeutic drugs to enhance their uptake and cancer cell killing.

Supporting Information

S1 Fig. Effect of AdFAST on metabolic activity in a variety of human cell lines. A) 786-O and SNB75 cells were infected at varying MOIs with AdEmpty or AdFAST and the relative metabolic activity was determined at 72 hpi. Three independent experiments were conducted in triplicate and the average is shown with the standard error of the mean (n = 3). Experiments were conducted in the same way as described in the MTS metabolic activity assays section of the Materials and Methods using DMEM media. *p<0.05 compared to PBS-treated cells. **p<0.05 comparing AdFAST to AdEmpty treated cells. B) Patient-derived normal primary lung cell lines U97N and U116N were subjected to the same experiment as described in Panel A. These cells were obtained at passage 2–4, and used for these experiments at less than passage 10. Results show the average of three replicates with the standard error of the mean. *p<0.05 compared to PBS-treated cells. **p<0.05 comparing AdFAST to AdEmpty treated cells. C and D) To confirm FAST protein expression, cells were infected with AdEmpty or AdFAST-HA at an MOI or 100 (or mock infected with PBS) and crude protein extracts were collected 72 hr later and assayed for FAST expression by immunoblot for the HA tag. As a loading control, the membranes were also probed with antibody to β-actin.

(TIF)

S1 Movie. Live-imaging analysis of 293 cells infected with AdRFP. 293 cells were infected at an MOI of 1 with AdRFP and subjected to live-imaging analysis 12 to 46 hpi using the Zeiss Axiovert 200M microscope with a 20x objective in a 37°C chamber with 5% CO2.

(MOV)

S2 Movie. Live-imaging analysis of 293 cells infected with AdFAST. 293 cells were infected at an MOI of 1 with AdFAST/RFP. Live imaging was conducted in a 37°C chamber
supplemented with 5% CO2. Images were taken from 12 hpi to 46 hpi at half hour intervals using the Zeiss Axiovert 200M microscope with a 20x objective.

(MOV)

Acknowledgments

We thank Melissa Geoffroy, Kalisa Campbell, and Natacha Provost for excellent technical assistance.

Author Contributions

Conceived and designed the experiments: CMW KLP JCB RJP. Performed the experiments: CMW KLP GT CC MAK TF. Analyzed the data: CMW KLP RJP. Contributed reagents/materials/analysis tools: CMW GT CC MAK TF JCB RJP. Wrote the paper: CMW KLP JCB RJP.

References

1. Ginn SL, Alexander IE, Edelstein ML, Abedi MR, Wixon J (2013) Gene therapy clinical trials worldwide to 2012—an update. The journal of gene medicine 15: 65–77. doi:10.1002/jgm.2698 PMID: 23355455
2. Lang FF, Bruner JM, Fuller GN, Aldape K, Prados MD, Chang S, et al. (2003) Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results. J Clin Oncol 21: 2508–2518. PMID: 12839017
3. Smith E, Breznik J, Lichty BD (2011) Strategies to enhance viral penetration of solid tumors. Human gene therapy 22: 1053–1060. doi:10.1089/hum.2010.227 PMID: 21443415
4. Bateman AR, Harrington KJ, Kottke T, Ahmed A, Melcher AA, Gough MJ, et al. (2002) Viral fusogenic membrane glycoproteins kill solid tumor cells by nonapoptotic mechanisms that promote cross presentation of tumor antigens by dendritic cells. Cancer Res 62: 6556–6567. PMID:12439252
5. Hoffmann D, Bayer W, Grunwald T, Wildner O (2007) Intratumoral expression of respiratory syncytial virus fusion protein in combination with cytokines encoded by adenoviral vectors as in situ tumor vaccine for colorectal cancer. Mol Cancer Ther 6: 1942–1950. PMID: 17620425
6. Ebert O, Shinozaki K, Koumioti C, Park MS, Garcia-Sastre A, Woo SL (2004) Syncytia induction enhances the oncolytic potential of vesicular stomatitis virus in virotherapy for cancer. Cancer research 64: 3265–3270. PMID: 15126368
7. Fu X, Tao L, Jin A, Vile R, Brenner MK, Zhang X (2003) Expression of a fusogenic membrane glycoprotein by an oncolytic herpes simplex virus potentiates the viral antitumor effect. Molecular therapy: the journal of the American Society of Gene Therapy 7: 748–754.
8. Le Boeuf F, Diallo JS, McCart JA, Thorne S, Falls T, Stanford M, et al. (2010) Synergistic interaction between oncolytic viruses augments tumor killing. Mol Ther 18: 888–895. doi: 10.1038/mt.2010.44 PMID: 20234341
9. Guedan S, Grases D, Rojas JJ, Gros A, Vilardell F, Vile R, et al. (2011) GALV expression enhances the therapeutic efficacy of an oncolytic adenovirus by inducing cell fusion and enhancing virus distribution. Gene Ther 19: 1048–1057. doi:10.1038/gt.2011.184 PMID: 22113313
10. Li H, Haviy YS, Derdeyn CA, Lam J, Coolidge C, Hunter E, et al. (2001) Human immunodeficiency virus type 1-mediated syncytium formation is compatible with adenovirus replication and facilitates efficient dispersion of viral gene products and de novo-synthesized virus particles. Human gene therapy 12: 2155–2165. PMID: 11779400
11. Bett AJ, Prevec L, Graham FL (1993) Packaging capacity and stability of human adenovirus type 5 vectors. J Virol 67: 5911–5921. PMID: 8371349
12. Saha B, Wong CM, Parks RJ (2014) The adenovirus genome contributes to the structural stability of the virion. Viruses 6: 3563–3583. doi:10.3390/v6093563 PMID: 25254384
13. Corcoran JA, Duncan R (2004) Reptilian reovirus utilizes a small type III protein with an external myristylated amino terminus to mediate cell-cell fusion. J Virol 78: 4342–4351. PMID: 15047847
14. Salsman J, Top D, Boutilier J, Duncan R (2005) Extensive syncytium formation mediated by the reovirus FAST proteins triggers apoptosis-induced membrane instability. J Virol 79: 8090–8100. PMID: 15956554
15. Brown CW, Stephenson KB, Hanson S, Kucharczyk M, Duncan R, Bell JC, et al. (2009) The p14 FAST protein of reptilian reovirus increases vesicular stomatitis virus neuropathogenesis. J Virol 83: 552–561. doi: 10.1128/JVI.01921-08 PMID: 18971262

16. Stojdl DF, Lichte BD, tenOever BR, Paterson JM, Power AT, Knowles S, et al. (2003) VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell 4: 263–275. PMID: 14585354

17. McCart JA, Ward JM, Lee J, Hu Y, Alexander HR, Libutti SK, et al. (2001) Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. Cancer Res 61: 8751–8757. PMID: 11751395

18. Graham FL, Smiley J, Russell WC, Nairn R (1977) Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 36: 59–74. PMID: 886304

19. Graham FL (1987) Growth of 293 cells in suspension culture. J Gen Virol 68: 937–940. PMID: 3819703

20. Chartier C, Degryse E, Gantzer M, Dieterle A, Pavirani A, Mehtali M (1996) Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli. Journal of virology 70: 4805–4810. PMID: 8676512

21. Campbell RE, Tour O, Palmer AE, Steinbach PA, Baird GS, Zacharias DA, et al. (2002) A monomeric red fluorescent protein. Proceedings of the National Academy of Sciences of the United States of America 99: 7877–7882. PMID: 12060735

22. Poulin KL, Lanthier RM, Smith AC, Christou C, Risco Quiroz M, Powell KL, et al. (2010) Retargeting of adenovirus vectors through genetic fusion of a single-chain or single-domain antibody to capsid protein IX. Journal of virology 84: 10074–10086. doi: 10.1128/JVI.02665-09 PMID: 20631131

23. Goulet BB, McFall ER, Wong CM, Kohary R, Parks RJ (2013) Supraphysiological expression of survival motor neuron protein from an adenovirus vector does not adversely affect cell function. Biochem Cell Biol 91: 252–264. doi: 10.1139/bcb-2012-0094 PMID: 23859020

24. Parks RJ, Krell PJ, Derbyshire JB, Nagy E (1994) Studies of fowlpox virus recombination in the generation of recombinant vaccines. Virus research 32: 283–297. PMID: 8079511

25. Sargent KL, Meulenbroek RA, Parks RJ (2004) Activation of adenoviral gene expression by protein IX is not required for efficient virus replication. Journal of virology 78: 5032–5037. PMID: 15113884

26. Ross PJ, Parks RJ (2009) Construction and characterization of adenovirus vectors. Cold Spring Harb Protoc 2009: pdb.pro5011.

27. Lieber A, He CY, Kirillova I, Kay MA (1996) Recombinant adenoviruses with large deletions generated by Cre-mediated excision exhibit different biological properties compared with first-generation vectors in vitro and in vivo. J Virol 70: 8944–8960. PMID: 8971024

28. Sugimoto J, Sugimoto M, Bemstein H, Jinno Y, Schust D (2013) A novel human endogenous retroviral protein inhibits cell-cell fusion. Sci Rep 3: 1462. doi: 10.1038/srep01462 PMID: 23492904

29. Schneider CA, Rasband WS, Eliceiri KW (2012) NIH Image to ImageJ: 25 years of image analysis. Nat Methods 9: 671–675. PMID: 22930834

30. Ilkow CS, Marguerie M, Batenchuk C, Mayer J, Ben Neriah D, Cousineau S, et al. (2015) Reciprocal cellular cross-talk within the tumor microenvironment promotes oncolytic virus activity. Nat Med 21: 530–536. doi: 10.1038/nm.3848 PMID: 25894825

31. Corcoran JA, Clancy EK, Duncan R (2011) Homomultimerization of the reovirus p14 fusion-associated small transmembrane protein during transit through the ER-Golgi complex secretory pathway. J Gen Virol 92: 162–166. doi: 10.1099/vir.0.026013-0 PMID: 20661318

32. Salsman J, Top D, Barry C, Duncan R (2008) A virus-encoded cell-cell fusion machine dependent on surrogate adhesins. PLoS pathogens 4: e1000016. doi: 10.1371/journal.ppat.1000116 PMID: 18369467

33. Top D, Barry C, Racine T, Ellis CL, Duncan R (2009) Enhanced fusion pore expansion mediated by the trans-acting Endodomain of the reovirus FAST proteins. PLoS pathogens 5: e1000331. doi: 10.1371/journal.ppat.1000331 PMID: 19266079

34. Ciechonska M, Duncan R (2014) Lysophosphatidylcholine reversibly arrests pore expansion during syncytium formation mediated by diverse viral fusogens. Journal of virology 88: 6528–6531. doi: 10.1128/JVI.00314-14 PMID: 24672027

35. Ciechonska M, Key T, Duncan R (2014) Efficient reovirus- and measles virus-mediated pore expansion during syncytium formation is dependent on annexin A1 and intracellular calcium. Journal of virology 88: 6137–6147. doi: 10.1128/JVI.00121-14 PMID: 24648446

36. Higuchi H, Bronk SF, Bateman A, Harrington K, Vile RG, Gores GJ (2000) Viral fusogenic membrane glycoprotein expression causes syncytia formation with bioenergetic cell death: implications for gene therapy. Cancer Res 60: 6396–6402. PMID: 11103804
37. Heise CC, Williams A, Olesch J, Kim DH (1999) Efficacy of a replication-competent adenovirus (ONYX-015) following intratumoral injection: intratumoral spread and distribution effects. Cancer Gene Ther 6: 499–504. PMID: 10608346

38. Shay JW, Bacchetti S (1997) A survey of telomerase activity in human cancer. European journal of cancer 33: 787–791. PMID: 9282118

39. Bodelon G, Labrada L, Martinez-Costas J, Benavente J (2002) Modification of late membrane permeability in avian reovirus-infected cells: viroporin activity of the S1-encoded nonstructural p10 protein. J Biol Chem 277: 17789–17796. PMID: 11893756

40. Errington F, Jones J, Merrick A, Bateman A, Harrington K, Gough M, et al. (2006) Fusogenic membrane glycoprotein-mediated tumour cell fusion activates human dendritic cells for enhanced IL-12 production and T-cell priming. Gene Ther 13: 138–149. PMID: 16136162